Table 5 Management of cardiovascular adverse event associated with monoclonal antibody

A. HF management (n = 49)

Count

Total

%

Was HF treated?

Yes

33

49

67.3%

ACE inhibitors

Yes

24

33

72.7%

ARBs

Yes

1

33

3%

Beta-blockers

Yes

20

33

60.6%

Diuretics

Yes

7

33

21.2%

Digoxin

Yes

2

33

6.1%

Other treatments

Hold trastuzumab

2

33

6.1%

B. HTN management (n = 34)

Count

Total

%

Was HTN treated?

Yes

34

34

100%

ACE inhibitor

Yes

18

34

52.9%

ARBs

Yes

1

34

2.9%

Diuretics

Yes

3

34

8.8%

CCBs

Yes

11

34

32.4%

Beta-blockers

Yes

9

34

26.5%

Other treatments

Spironolactone

1

34

2.9%

C. IHD management (n = 2)

Count

Total

%

Was IHD treated?

Yes

2

2

100%

ASA

Yes

1

2

50%

ACE inhibitors

Yes

2

2

100%

Beta-blockers

Yes

2

2

100%

Heparin

Yes

1

2

50%

Other treatments

Clopidogrel and Simvastatin

1

2

50%

D. Arrhythmia management (n = 3)

Count

Total

%

Was arrhythmia treated?

Yes

2

3

66.7%

Class II (beta-blockers)

Yes

2

2

100%

Class III (K channel-blockers)

Yes

1

2

50%

Class IV (Ca channel-blockers)

Yes

1

2

50%

Other treatments

Enoxaparin

1

2

50%

E. Thromboembolism management (n = 32)

Count

Total

%

Was thromboembolic event treated?

Yes

29

32

90.6%

Warfarin

Yes

2

29

6.9%

LMWH

Yes

27

29

93.1%

UFH

Yes

3

29

10.3%

Other treatments

Hold bevacizumab

2

29

6.9%

F. Hemorrhage management (n = 25)

Count

Total

%

Was hemorrhage treated?

Yes

10

25

40%

FFP

Yes

1

10

10%

Platelet concentrates

Yes

1

10

10%

Surgery

Yes

1

10

10%

Other treatments

Yes

7

10

70%